Uses of oxygenated cholesterol sulfates (ocs)

Abstract

Methods of preventing and/or treating ischemia, organ dysfunction and/or organ failure, including multiple organ dysfunction syndrome (MODS), and necrosis and apoptosis associated with organ dysfunction/failure, are provided. For instance, the methods involve contacting organ(s) with an oxygenated cholesterol sulfate (OCS), e.g. 5-cholesten-3,25-diol, 3-sulfate (25HC3S). The organ(s) may be in vivo (e.g. in a patient that is treated with the OCS) or ex vivo (e.g. an organ that has been harvested from a donor and is to be transplanted).

1 .- 18 . (canceled) 
     
     
         19 . A method of prophylactically treating or treating sepsis in a subject in need thereof, comprising
 administering to the subject an amount of 5-cholesten-3,25-diol, 3-sulfate (25HC3S) or pharmaceutically acceptable salt thereof that is sufficient to prophylactically treat or treat sepsis.   
     
     
         20 . The method of  claim 19 , wherein the administering is performed by at least one of parenterally, intravenously, intramuscularly, subcutaneously, by intradermal injection, by intraperitoneal injection, transdermally, sublingually, rectally, by buccal delivery, by inhalation of an aerosol, intravaginally, intranasally, and topically. 
     
     
         21 . The method of  claim 19 , wherein the administering is performed by at least one of orally, subcutaneously, and intramuscularly. 
     
     
         22 . The method of  claim 19 , wherein the administering is performed intravenously. 
     
     
         23 . The method of  claim 19 , wherein the administering comprises injection. 
     
     
         24 . The method of  claim 19 , wherein the 25HC3S or pharmaceutically acceptable salt thereof is administered in a formulation further comprising a pharmaceutically acceptable carrier. 
     
     
         25 . The method of  claim 19 , wherein the 25HC3S or pharmaceutically acceptable salt thereof comprises a pharmaceutically acceptable salt of 25HC3S. 
     
     
         26 . The method of  claim 19 , wherein the 25HC3S or pharmaceutically acceptable salt thereof is administered at a dose ranging from about 0.001 mg/kg to about 100 mg/kg. 
     
     
         27 . The method of  claim 19 , wherein the 25HC3S or pharmaceutically acceptable salt thereof is administered at a dose ranging from about 0.001 mg/kg to about 10 mg/kg. 
     
     
         28 . The method of  claim 19 , wherein the 25HC3S or pharmaceutically acceptable salt thereof is administered at a dose ranging from about 0.1 mg/kg to about 10 mg/kg. 
     
     
         29 . The method of  claim 19 , wherein the administering is performed from once to 3 times per day. 
     
     
         30 . The method of  claim 21 , wherein the 25HC3S or pharmaceutically acceptable salt thereof is administered at a dose ranging from about 0.001 mg/kg to about 100 mg/kg. 
     
     
         31 . The method of  claim 22 , wherein the 25HC3S or pharmaceutically acceptable salt thereof is administered at a dose ranging from about 0.001 mg/kg to about 100 mg/kg. 
     
     
         32 . The method of  claim 23 , wherein the 25HC3S or pharmaceutically acceptable salt thereof is administered at a dose ranging from about 0.001 mg/kg to about 100 mg/kg. 
     
     
         33 . The method of  claim 24 , wherein the 25HC3S or pharmaceutically acceptable salt thereof is administered at a dose ranging from about 0.001 mg/kg to about 100 mg/kg. 
     
     
         34 . The method of  claim 25 , wherein the 25HC3S or pharmaceutically acceptable salt thereof is administered at a dose ranging from about 0.001 mg/kg to about 100 mg/kg. 
     
     
         35 . The method of  claim 21 , wherein the 25HC3S or pharmaceutically acceptable salt thereof is administered at a dose ranging from about 0.001 mg/kg to about 10 mg/kg. 
     
     
         36 . The method of  claim 22 , wherein the 25HC3S or pharmaceutically acceptable salt thereof is administered at a dose ranging from about 0.001 mg/kg to about 10 mg/kg. 
     
     
         37 . The method of  claim 24 , wherein the 25HC3S or pharmaceutically acceptable salt thereof is administered at a dose ranging from about 0.001 mg/kg to about 10 mg/kg. 
     
     
         38 . The method of  claim 25 , wherein the 25HC3S or pharmaceutically acceptable salt thereof is administered at a dose ranging from about 0.001 mg/kg to about 10 mg/kg.